Compare MTB & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTB | IQV |
|---|---|---|
| Founded | 1856 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4B | 36.4B |
| IPO Year | N/A | 2013 |
| Metric | MTB | IQV |
|---|---|---|
| Price | $207.48 | $226.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 15 |
| Target Price | $216.08 | ★ $236.93 |
| AVG Volume (30 Days) | 990.2K | ★ 1.5M |
| Earning Date | 01-16-2026 | 02-05-2026 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | ★ 19.77 | N/A |
| EPS | ★ 16.19 | 7.30 |
| Revenue | $9,080,000,000.00 | ★ $15,904,000,000.00 |
| Revenue This Year | $12.85 | $6.14 |
| Revenue Next Year | $3.67 | $5.35 |
| P/E Ratio | ★ $12.75 | $30.83 |
| Revenue Growth | ★ 6.84 | 3.85 |
| 52 Week Low | $150.75 | $134.65 |
| 52 Week High | $208.26 | $234.30 |
| Indicator | MTB | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 69.90 | 56.45 |
| Support Level | $202.73 | $219.91 |
| Resistance Level | $208.26 | $225.80 |
| Average True Range (ATR) | 3.42 | 4.24 |
| MACD | 0.32 | -0.32 |
| Stochastic Oscillator | 92.88 | 92.20 |
M&T Bank is a US regional bank with roughly $210 billion in assets as of June 30, 2025. Headquartered in Buffalo, New York, the bank's footprint is mostly concentrated in New England and the US Mid-Atlantic. M&T Bank boasts a community banking approach, and boasts over 900 branches in 13 states and Washington, D.C. Apart from retail and commercial banking, M&T Bank also has wealth management operations through Wilmington Trust and a partnership with LPL Financial, and a corporate trust businesses.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.